NCT03307447View on ClinicalTrials.gov

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

September 30, 2021

Study Completion Date

December 31, 2021

Conditions
Psoriasis Vulgaris
Interventions
DRUG

Secukinumab

Secukinumab 300 mg subcutaneous injection

Trial Locations (1)

11209

RECRUITING

VA NY Harbor Healthcare System, Brooklyn

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Narrows Institute for Biomedical Research

OTHER